Technology area: Biotechnology & Pharmaceuticals
75 pending office actions • 47 clients • 68 examiners • 51 art units • 0 of 75 (0%) have an AI response strategy ready
CHALKER FLORES, LLP has 76 pending office actions in Biotechnology & Pharmaceuticals and 4174 career applications. The active docket and application history show substantial prosecution activity in the technology area, giving practitioners a meaningful basis for evaluating experience and current workload.
The resolved allowance rate is 82.36%, with an average of 4.46 office actions per allowance. The rate reflects favorable outcomes among resolved matters, while the action average indicates that reaching allowance commonly involves repeated examiner engagement. Applicants can use these measures to plan for sustained prosecution, including amendment cycles, technical development, and response deadlines.
Based on the USPTO statutory response window for each pending office action. 30 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 30 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 3 (4%) |
| §101 + other | 9 (12%) |
| §103 only | 18 (24%) |
| §102 only | 2 (3%) |
| §112 only | 7 (9%) |
| Double-patenting only | 2 (3%) |
| Double-patenting + other | 9 (12%) |
| Multi-statute (no §101) | 25 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, SAVITHA M | 2 | 60.7% | +29.7% |
| BONAPARTE, AMY C | 2 | 79.1% | +23.5% |
| LITTLE, ANNA VICTORIA | 2 | 76.9% | +22.8% |
| GALSTER, SAMUEL LEONARD | 2 | 52.1% | +42.2% |
| GREEN, MALIA NICOLE | 2 | — | — |
| FIEBIG, RUSSELL G | 2 | 62.6% | +25.0% |
| WHITE, ASHLEY TAYLOR | 2 | 23.8% | +36.7% |
| KIM, DANIELLE A | 1 | 36.6% | +51.9% |
| COLEMAN, BRENDA LIBBY | 1 | 74.8% | +15.7% |
| BATES, KEENAN ALEXANDER | 1 | 44.9% | +79.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17768537 | Bi-Peptide with Affinity to Extracellular Matrix Proteins or Cells and to Growth Factors for Tissue Healing and Regeneration | STEELE, AMBER D | 280d overdue |
| 17567400 | Wireless Communication Methods | RENNER, BRANDON M | 87d overdue |
| 18468050 | Hook-Spring Plate for Growth Modulation of Immature Rib to Correct Early Onset Scoliosis | RAMANA, ANURADHA | 73d overdue |
| 18137016 | DISTRIBUTED MICROWAVE QUANTUM COMPUTING SYSTEM | HOSSAIN, MOAZZAM | 67d overdue |
| 17925662 | Agent for Increasing Content of IgA Antibody in Milk | KOROTCHKINA, LIOUBOV G | 52d overdue |
| 18322942 | ANALYSIS OF PROTEIN KINASES IN LIVE CELLS | WHITE, ASHLEY TAYLOR | 29d overdue |
| 17462414 | ROTORCRAFT FALL RESTRAINT PROTECTION ATTACH POINTS AND MECHANISM SYSTEMS | EDWARDS, LOREN C | 28d overdue |
| 18887482 | Method and System for Generating Solution Explanations for Learning Problems | UTAMA, ROBERT J | 15d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18322942 | ANALYSIS OF PROTEIN KINASES IN LIVE CELLS | WHITE, ASHLEY TAYLOR | 29d overdue |
| 18770850 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | BONAPARTE, AMY C | 14d |
| 18678550 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | BONAPARTE, AMY C | 14d |
| 18693693 | Triple Drug Combination (Metformin, Simvastatin, Digoxin) for Targeted Treatment of Colorectal Cancer | GALSTER, SAMUEL LEONARD | 63d |
| 19539174 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE AND DERIVATIVES THEREOF, AND TABLETS THEREOF | KIM, DANIELLE A | — |
| 18975409 | Modified Tetracycline for Treatment of Alcohol Use Disorder, Pain and Other Disorders Involving Potential Inflammatory Processes | COLEMAN, BRENDA LIBBY | — |
| 18865121 | NOVEL METHOD FOR PRESERVING PLATELETS | BATES, KEENAN ALEXANDER | — |
| 18818731 | BIOMARKERS USEFUL IN THE TREATMENT OF SUBJECTS HAVING DISEASES OF THE EYE | RAO, SAVITHA M | — |
| Art Unit | Apps |
|---|---|
| 1643 | 5 |
| 1653 | 4 |
| 3773 | 3 |
| 1671 | 3 |
| 1628 | 3 |
| 1613 | 2 |
| 1624 | 2 |
| 3715 | 2 |
| 4100 | 2 |
| 1691 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19539174 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE AND DERIVATIVES THEREOF, AND TABLETS THEREOF | Nacuity Pharmaceuticals, Inc. | KIM, DANIELLE A | 1613 | §103§112DP | Non-Final OA | — | Pending | Feb 13, 2026 |
| 18975409 | Modified Tetracycline for Treatment of Alcohol Use Disorder, Pain and Other Disorders Involving Potential Inflammatory Processes | Texas Tech University System | COLEMAN, BRENDA LIBBY | 1624 | §102§103§112DP | Non-Final OA | — | Pending | Dec 10, 2024 |
| 18865121 | NOVEL METHOD FOR PRESERVING PLATELETS | Adiposeeds, Inc. | BATES, KEENAN ALEXANDER | 1631 | §102§112 | Non-Final OA | — | Pending | Nov 12, 2024 |
| 18910067 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders | Arog Pharmaceuticals, Inc. | GEMBEH, SHIRLEY V | 1615 | DP | Non-Final OA | — | Pending | Oct 09, 2024 |
| 18887252 | Method and System for Generating Learning Problems | Mata Edu, Inc. | FRENCH, CORRELL T | 3715 | §101§103§112 | Final Rejection | 60d | Pending | Sep 17, 2024 |
| 18887482 | Method and System for Generating Solution Explanations for Learning Problems | Mata Edu, Inc. | UTAMA, ROBERT J | 3715 | §101 | Final Rejection | 15d overdue | Pending | Sep 17, 2024 |
| 18830839 | Method and System for Visualizing Problem Solving Results | Mata Edu, Inc. | HULL, JAMES B | 4100 | §101 | Final Rejection | — | Pending | Sep 11, 2024 |
| 18823052 | Sealing System and Method for Pressurized Sand Damper | Southern Methodist University | KING, BRADLEY T | 3616 | §102§103§112 | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18818731 | BIOMARKERS USEFUL IN THE TREATMENT OF SUBJECTS HAVING DISEASES OF THE EYE | The Johns Hopkins University | RAO, SAVITHA M | 1691 | §102§103DP | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18814725 | Systems and Methods for Angiogenic Treatment in Wound Healing | Venturis Therapeutics, Inc. | MOLOYE, TITILAYO | 1632 | §112DP | Non-Final OA | — | Pending | Aug 26, 2024 |
| 18840269 | PROTEIN BIOMARKERS OF INFLAMMATORY ACTIVITY IN MULTIPLE SCLEROSIS | The Board Of Regents Of The University Of Oklahoma | COUNTS, GARY W | 1678 | §101§112 | Non-Final OA | — | Pending | Aug 21, 2024 |
| 18776848 | Method and System for Recording Clinical Trial Data Using Generative AI Model | Crscube, Inc. | ERICKSON, BENNETT S | 3683 | §101§103 | Non-Final OA | 3d overdue | Pending | Jul 18, 2024 |
| 18770850 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | Nacuity Pharmaceuticals, Inc. | BONAPARTE, AMY C | 1692 | §103 | Final Rejection | 14d | Pending | Jul 12, 2024 |
| 18728142 | Microwave Architecture for Passive Sensing Applications | Texas Tech University System | GOOD, KENNETH W | 3648 | §103 | Final Rejection | — | Pending | Jul 11, 2024 |
| 18770014 | ANCHOR AND INTERBODY FOR INTERBODY FUSION | Evolution Spine, LLC | LITTLE, ANNA VICTORIA | 3773 | §103 | Non-Final OA | — | Pending | Jul 11, 2024 |
| 18719116 | REVERSAL OF SENESCENCE BY ULTRASOUND IRRADIATION | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | CWERN, JONATHAN | 3797 | §102§103 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18738665 | COMPOSITIONS AND METHODS FOR TREATING DRY EYE | Genetic Disease Investigators, LLC | RAO, SAVITHA M | 1691 | §103Other | Non-Final OA | — | Pending | Jun 10, 2024 |
| 18678550 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | Nacuity Pharmaceuticals, Inc. | BONAPARTE, AMY C | 1692 | §103 | Final Rejection | 14d | Pending | May 30, 2024 |
| 18709941 | Negative Electrode Active Material for Secondary Battery, and Secondary Battery Using Same | National Institute Of Advanced Industrial Science And Technology | HANYON, SAMANTHA LEE | §103 | Non-Final OA | — | Pending | May 14, 2024 | |
| 18628192 | Bone Reshaping Tool and Method | Texas Scottish Rite Hospital For Children | SIPP, AMY R. | 3775 | §103§112 | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18626439 | Preparation of Chitin Nanocrystals and Nanowhiskers from Crustacean Biomass Using Ionic Liquid | Texas Tech University System | GALSTER, SAMUEL LEONARD | 1693 | §102§103§112 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18697938 | Selenium Containing Antimicrobial Compound as a Reacitve Dye and Cross-Linking Treatment for Textile Applications | Texas Tech University System | STEVENS, MARK V | 1613 | §102§103§112DP | Non-Final OA | — | Pending | Apr 02, 2024 |
| 18693693 | Triple Drug Combination (Metformin, Simvastatin, Digoxin) for Targeted Treatment of Colorectal Cancer | Whispergenics. Inc. | GALSTER, SAMUEL LEONARD | 1693 | §103DP | Non-Final OA | 63d | Pending | Mar 20, 2024 |
| 18693225 | Rapid Acting Vaccine Against Nipah Virus | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | LY, KRISTINA ELISABETH | 1671 | §103§112 | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18692976 | Method for Promoting Production of Exopolysaccharide by Bifidobacterium Bacteria | Tohoku University | EPSTEIN, TODD MATTHEW | 1652 | §101§102§112 | Final Rejection | 75d | Pending | Mar 18, 2024 |
| 18685939 | Antibody Specifically Binding to CD47, Recombinant Oncolytic Virus Thereof and Use Thereof | Shanghai Sinobay Biotechnology Co., Ltd. | SHUPE, ELIZABETH A | 1643 | §102§103§112Other | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18683442 | METHOD FOR TREATING IMMUNE DISEASES USING CALCINEURIN INHIBITOR AND STEM CELLS | Kangstem Biotech Co., Ltd. | BARRON, SEAN C | 1653 | §103 | Final Rejection | — | Pending | Feb 13, 2024 |
| 18390880 | VARIANT-SPECIFIC EXOGENOUS DNA TEMPLATE-FREE CORRECTION OF PATHOGENIC VARIANTS | Hadasit Medical Research Services And Development Ltd. | MEYERING, SHABANA SHABBEER | 4100 | §102§103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18539931 | AGENT FOR ANTI-AGING OR FOR CELLULAR REJUVENATION | Tohoku University | BORALSKY, LUKE ALAN | 1624 | §102§103§112Other | Final Rejection | — | Pending | Dec 14, 2023 |
| 18568393 | REMOTELY CONTROLLABLE RESCUE VESSEL | Australian Droid & Robot Pty Ltd. | BURGESS, MARC R | 3615 | §103§112 | Non-Final OA | 23d | Pending | Dec 08, 2023 |
| 18522587 | IMPEDANCE-BASED NEUTRALIZING ANTIBODY DETECTION BIOSENSOR WITH APPLICATION TO SARS-CoV-2 INFECTION | Southern Methodist University | SIFFORD, JEFFREY MARK | 1671 | §103§112 | Final Rejection | — | Pending | Nov 29, 2023 |
| 18564913 | Suppressive T Cell Populations and Methods of Cancer Immunotherapy | UNIVERSITY OF SOUTHAMPTON | GURLEY, JAMI MICHELLE | 1647 | §101§103§112 | Non-Final OA | — | Pending | Nov 28, 2023 |
| 18517623 | Non-Small Cell Lung Cancer Diagnosis and Treatment | West Virginia University | POHNERT, STEVEN C | 1683 | §103 | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18499751 | SPINAL IMPLANT | Evolution Spine | LITTLE, ANNA VICTORIA | 3773 | §103 | Final Rejection | — | Pending | Nov 01, 2023 |
| 18492092 | COMPOSITIONS AND METHODS FOR THERMAL SKIN TREATMENT WITH METAL NANOPARTICLES | Coronado Aesthetics, LLC | YU, HONG | 1614 | §103 | Non-Final OA | 89d overdue | Pending | Oct 23, 2023 |
| 18489983 | CHEMOKINE RECEPTOR 8 (CCR8) ANTIBODIES | Ibio, Inc. | GREEN, MALIA NICOLE | 1643 | §112 | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18484635 | EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III ANTIBODIES | Ibio, Inc. | GREEN, MALIA NICOLE | 1643 | §103§112 | Non-Final OA | — | Pending | Oct 11, 2023 |
| 18482147 | Use of Black Solider Fly Larvae as Palatant / Palatability Enhancer for use in edible pet products | Npic | KOHLER, STEPHANIE A | 1791 | §103 | Non-Final OA | 59d overdue | Pending | Oct 06, 2023 |
| 18470999 | Neuraminidase-Inhibited Influenza Virus | Vaxdome Inc. | FOLEY, SHANON A | 1671 | §103 | Final Rejection | — | Pending | Sep 20, 2023 |
| 18468050 | Hook-Spring Plate for Growth Modulation of Immature Rib to Correct Early Onset Scoliosis | Texas Scottish Rite Hospital For Children | RAMANA, ANURADHA | 3775 | §102§103§112 | Non-Final OA | 73d overdue | Pending | Sep 15, 2023 |
| 18044813 | METHOD FOR PREPARING INJECTABLE INJECTION COMPOSITION DERIVED FROM ANIMAL CARTILAGE, AND USE THEREOF | Kangstem Biotech Co., Ltd. | FIEBIG, RUSSELL G | 1655 | §103 | Non-Final OA | — | Pending | Aug 30, 2023 |
| 18457037 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | Signpath Pharma, Inc. | O DELL, DAVID K | 1621 | §102§112 | Final Rejection | — | Pending | Aug 28, 2023 |
| 18348811 | Ophthalmic Implant | Evonik Corporation | SCHLIENTZ, LEAH H | 1618 | §103 | Non-Final OA | — | Pending | Jul 07, 2023 |
| 18260012 | LIPIDS THAT REDUCE LUNG DAMAGE, IMPROVE PULMONARY FUNCTION AND DECREASE PRO-INFLAMMATORY CYTOKINES | Signpath Pharma, Inc. | RODRIGUEZ, RAYNA B | 1628 | §112 | Final Rejection | — | Pending | Jun 29, 2023 |
| 18334212 | Compositions and Methods for Treating Osteonecrosis | Texas Scottish Rite Hospital For Children | CHANDRA, GYAN | 3783 | §102§103§112DP | Non-Final OA | — | Pending | Jun 13, 2023 |
| 18333812 | METHOD FOR PREPARING INJECTABLE INJECTION COMPOSITION DERIVED FROM ANIMAL CARTILAGE, AND USE THEREOF | Atems Co., Ltd. | FIEBIG, RUSSELL G | 1655 | §103§112Other | Non-Final OA | — | Pending | Jun 13, 2023 |
| 18322942 | ANALYSIS OF PROTEIN KINASES IN LIVE CELLS | University of North Carolina - Chapel Hill | WHITE, ASHLEY TAYLOR | 1653 | §103§112DP | Final Rejection | 29d overdue | Pending | May 24, 2023 |
| 18035160 | HLA CLASS II-RESTRICTED TCRS AGAINST THE KRAS G12>V ACTIVATING MUTATION | The Regents of the University of California | GODDARD, LAURA B | 1642 | §102§112Other | Non-Final OA | — | Pending | May 03, 2023 |
| 18249988 | CARRIER PEPTIDE FRAGMENT AND USE THEREOF | Toagosei Co., Ltd. | NOAKES, SUZANNE MARIE | 1656 | §102 | Non-Final OA | — | Pending | Apr 21, 2023 |
| 18137016 | DISTRIBUTED MICROWAVE QUANTUM COMPUTING SYSTEM | Anyon Computing Inc. | HOSSAIN, MOAZZAM | 2898 | §102§103 | Final Rejection | 67d overdue | Pending | Apr 20, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial82.4% of resolved applications prosecuted by Chalker Flores, LLP were allowed, across 4,174 applications in USPTO records.
4.46 office actions per allowed application on average.
75 pending office actions as of October 2026, for 47 clients, before 68 examiners in 51 art units.
